Vivo Capital related stories
All articles and analysis
Biospring Partners leads growth investment in spray drying CDMO Serán BioscienceBend, Oregon-based Serán Bioscience provides development, analytical and clinical manufacturing services to pharmaceutical and biotechnology companies.
Vivo Capital taps Neetesh Kumar as managing partnerKumar will co-lead Vivo’s buyout and private equity investment strategy with a focus on the US market and help establish the firm’s presence in New York.
LBO France to sell Dutscher to Vivo CapitalDutscher is a European consumables and equipment distribution company.
Fundraising for Vivo Capital’s 10th fund stretches into the fourth yearLast year, the firm closed its third cycle of the evergreen fund dubbed Vivo Opportunity Fund with over $740m in commitments.
Venture capital’s 2026 Rising Stars: A-GA principal focused on AI early-stage investments, a partner concentrating in biotechnology and a principal involved with women’s health research are among those on VCJ's 2026 list of 40 Rising Stars under the age of 40.
A new prescription for US healthcareUnder the second Trump administration, policy change and regulatory scrutiny are steering healthcare investors’ attention towards a different set of opportunities.
Evergreen funds: Good or bad for LPs?Nicole Musicco, former CIO of CalPERS, warns that evergreen funds may lead to a more transactional dynamic between manager and investor.
Vivo Capital closes on $740m for third cycle of evergreen public fundThe fund's private markets-style structure 'allows us to apply a venture capital mindset to publicly traded biotech companies,' says managing partner Gaurav Aggarwal.
Arizona Public Safety hits pause on VC investmentsThe public pension has committed a combined $95m to venture funds managed by Upfront Ventures, StepStone Group and Mission BioCapital since 2019.
KGI Life approves $60m in commitmentsThe Taiwan-based insurance company has backed two private equity funds.